Quantum Cyber N v (MYNZ) - News Archive

Mainz Biomed, an innovative biotechnology company focused on the development of solutions for colorectal cancer detection, has announced a significant agreement with Quest Diagnostics. This partnership aims to provide e...

In a significant development within the biopharmaceutical landscape, Mainz Biomed, a dedicated player in the field of molecular genetic testing, has announced the completion of an $8.0 million follow-on offering priced...

In the ever-evolving landscape of healthcare, the integration of artificial intelligence (AI) has become a cornerstone of innovation, particularly in the challenging field of cancer diagnostics. Mainz Biomed N.V. (NASDA...

Artificial Intelligence (AI) has emerged as a pivotal tool in pharmaceutical sciences, particularly in the realm of biomarker discovery. In this context, Mainz Biomed N.V. (NASDAQ: MYNZ) has announced a strategic partne...

Enhanced ColoAlert: Mainz Biomed Revolutionizes Colon Cancer Screening with Advanced Features and Unmatched User Convenience In a significant stride toward optimizing colon cancer screening, Mainz Biomed recently unveil...

Mainz Biomed Presented with Poster of Distinction at Digestive Disease Week, Setting the Stage for Upcoming FDA TrialIn a recent press release, Mainz Biomed announced that it has received the highly regarded Poster of D...

Mainz Biomed Collaborates with Trusted Health Advisors to Revolutionize Early Colorectal Cancer Diagnosis and Employee Healthcare In a groundbreaking move towards transforming colorectal cancer (CRC) diagnosis and impro...

Mainz Biomed Collaborates with TomaLab to Enhance Availability of ColoAlert in Italy In an effort to improve colorectal cancer detection rates and expand the availability of its pioneering diagnostic tool, ColoAlert, Ma...

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for EmployeesMainz Biomed N.V., a leading healthcare company specializing in innovative diagnostic solutions, has...

In a recent groundbreaking study, Mainz Biomed N.V. announced positive topline results from the U.S. eAArly DETECT study, validating the efficacy of their novel mRNA biomarkers. These results have positioned Mainz Biome...